Bristol Myers Squibb (CELG-RI) Profit After Tax Growth (5y) (2014 - 2026)

Bristol Myers Squibb (CELG-RI) Profit After Tax Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 5.79%
Dec 31, 2025 16.09%
Sep 30, 2025 3.22%
Jun 30, 2025 15.14%
Mar 31, 2025 38.94%
Dec 31, 2024 15.53%
Sep 30, 2024 -2.32%
Jun 30, 2024 3.25%
Mar 31, 2024 -55.00%
Dec 31, 2023 8.76%
Sep 30, 2023 0.34%
Jun 30, 2023 -59.82%
Mar 31, 2023 -67.98%
Dec 31, 2022 23.53%
Sep 30, 2022 13.73%
Jun 30, 2022 9.18%
Mar 31, 2022 -68.15%
Dec 31, 2021 21.65%
Sep 30, 2021 4.94%
Jun 30, 2021 -1.98%